Author(s): CuencaEstrella M, GomezLopez A, AlastrueyIzquierdo A, BernalMartinez L, Cuesta I, , CuencaEstrella M, GomezLopez A, AlastrueyIzquierdo A, BernalMartinez L, Cuesta I,
Abstract Share this page
Abstract The commercial technique Vitek 2 system for antifungal susceptibility testing of yeast species was evaluated. A collection of 154 clinical yeast isolates, including amphotericin B- and azole-resistant organisms, was tested. Results were compared with those obtained by the reference procedures of both the CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Two other commercial techniques approved for clinical use, the Etest and the Sensititre YeastOne, were included in the comparative exercise as well. The average essential agreement (EA) between the Vitek 2 system and the reference procedures was >95\%, comparable with the average EAs observed between the reference procedures and the Sensititre YeastOne and Etest. The EA values were >97\% for Candida spp. and stood at 92\% for Cryptococcus neoformans. Intraclass correlation coefficients (ICC) between the commercial techniques and the reference procedures were statistically significant (P<0.01). Percentages of very major errors were 2.6\% between Vitek 2 and the EUCAST technique and 1.6\% between Vitek 2 and the CLSI technique. The Vitek 2 MIC results were available after 14 to 18 h of incubation for all Candida spp. (average time to reading, 15.5 h). The Vitek 2 system was shown to be a reliable technique to determine antifungal susceptibility testing of yeast species and a more rapid and easier alternative for clinical laboratories than the procedures developed by either the CLSI or EUCAST.
This article was published in J Clin Microbiol
and referenced in Journal of AIDS & Clinical Research